PRRT2 and glioblastoma: As our optimized combination strategy decreased PI3K/Akt and neuregulin signaling (a consequence of PKC inhibition), reduced glioblastoma signaling was predicted corresponding to the reduced expression of GFAP (Figure 6E, F and Supplemental Table 8).